Semaglutide Shortage Update

Last updated: Check with your account manager for the most current shortage status as this area evolves rapidly.

Current FDA Shortage Status

Semaglutide (Ozempic®, Wegovy®) has experienced intermittent shortage designations due to unprecedented demand for GLP-1 medications for weight management. The FDA Drug Shortage Database tracks current status.

When semaglutide is on the FDA shortage list, licensed compounding pharmacies may legally compound semaglutide for individual patients based on valid prescriptions.

Impact on Compounding

FDA shortage status directly affects the ability of 503A pharmacies to compound semaglutide:

• During shortage: Compounding is permitted under 503A for individual patient prescriptions
• Post-shortage: Regulatory status may change. 503A pharmacies comply with any FDA or state guidance

Promise Pharmacy Supply Status

Promise Pharmacy maintains consistent semaglutide supply for existing provider partners. We source pharmaceutical-grade ingredients from verified suppliers and maintain buffer inventory.

• Semaglutide: In stock — accepting orders from provider accounts
• Tirzepatide: In stock — tirzepatide details

What Providers Should Do

1. Establish a provider account now to ensure access when you need it
2. Monitor FDA shortage list updates through your account manager
3. Consider stocking both semaglutide and tirzepatide to offer patients alternatives
4. Review your state's compounding regulations with our compliance team